The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...

Life Science Washington, the state's life sciences industry association, today announced the expansion of its board of directors with the addition of nine new members, representing distinguished ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...